Affle (India) Limited vs Laurus Labs Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Affle (India) Limited (Advertising technology) and Laurus Labs Limited (Pharmaceuticals and contract development/manufacturing) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Laurus Labs Limited leads on Revenue (approx.).
Laurus Labs Limited leads on Revenue (approx.).
Choose Affle if you want exposure to mobile-first advertising technology, performance-based ad models, and growth markets across India and Southeast Asia, while accepting dependence on mobile ad budgets and competitive margin pressure. Choose Laurus Labs if you prefer pharmaceuticals manufacturing and CDMO exposure, backed by chemistry capabilities and integrated API-to-formulation operations, while accepting regulatory, pricing, and project-volatility risks. The right choice depends on whether the buyer prioritizes adtech growth-market exposure or pharmaceutical manufacturing and CDMO capabilities.
Grounded in the verified figures and SWOT shown — guidance, not investment advice.
Head-to-head highlights
| Metric | Affle (India) Limited | Laurus Labs Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | Approximately ₹1,800-1,900 crore | Around INR 5,000 crore, approximate and unverified | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Affle (India) Limited
Advertising technology · India
Affle (India) Limited is an Indian advertising technology company focused on mobile marketing, user acquisition, and consumer intelligence. Its platforms help advertisers acquire, engage, and monetize users across mobile apps and digital channels, with a strong focus on India and other emerging markets.
Verified financials
No source-verified financials available.
Strengths
- Strong mobile-first adtech specialization
- Performance-based advertising model aligned with advertiser ROI
- Presence across India, Southeast Asia, and other growth markets
- Portfolio expanded through acquisitions such as Jampp, mediasmart, and RevX
Weaknesses
- Smaller scale than global platform giants
- Dependence on mobile advertising budgets
- Business complexity from multiple acquired platforms
- Exposure to margin pressure in competitive performance marketing
Opportunities
- Growth in mobile app ecosystems across emerging markets
- Rising advertiser demand for measurable performance marketing
- Expansion of AI-driven campaign optimization and consumer intelligence
- Cross-selling across acquired adtech platforms
Threats
- Privacy regulation and mobile identifier restrictions
- Competition from large walled-garden platforms
- Ad fraud and brand-safety concerns in digital advertising
- Macroeconomic slowdowns affecting advertising spend
Laurus Labs Limited
Pharmaceuticals and contract development/manufacturing · India
Laurus Labs Limited is an Indian pharmaceutical company focused on active pharmaceutical ingredients, finished dosage formulations, and contract development and manufacturing services. The company is known for its presence in antiretroviral medicines and has been expanding into non-ARV APIs, CDMO services, biotechnology, and specialty ingredients.
Verified financials
No source-verified financials available.
Strengths
- Strong chemistry and manufacturing capabilities
- Established presence in antiretroviral APIs and formulations
- Growing CDMO and custom synthesis platform
- Integrated operations across APIs and finished dosage forms
Weaknesses
- Exposure to pricing pressure in commoditized pharmaceutical products
- Dependence on regulated-market compliance and inspections
- Revenue volatility from project-based CDMO work
- Margin sensitivity to raw material and energy costs
Opportunities
- Expansion in CDMO and custom synthesis for global pharma clients
- Diversification into non-ARV therapies and specialty APIs
- Growth in biotechnology and fermentation-based manufacturing
- Increased demand for India-based pharmaceutical supply chains
Threats
- Regulatory actions or compliance setbacks
- Intense competition from Indian and Chinese manufacturers
- Customer concentration in certain product areas
- Currency fluctuations and global pricing pressure
Frequently asked
Answered from source-verified figures on this page.
Affle (India) Limited vs Laurus Labs Limited: which company leads overall?
Laurus Labs Limited leads on Revenue (approx.).
Related market reports
Deep-dive intelligence on the markets these companies compete in.
India Defense Equipment Market — Intelligence Report
India Semiconductor Market — Chip Manufacturing, Electronics Ecosystem & Investment Outlook
Global Industrial Automation & Robotics Market — Intelligence Report
Global Streaming & Connected TV Advertising Market — Intelligence Report
AI Analyst
Insights and answers generated live from Affle (India) Limited vs Laurus Labs Limited's verified data. Modeled estimates — not investment advice.
- Affle (India) Limited is an Indian advertising technology company focused on mobile marketing, user acquisition, and consumer intelligence.
- Affle’s platforms help advertisers acquire, engage, and monetize users across mobile apps and digital channels, with emphasis on India and other emerging markets.
- Laurus Labs Limited is an Indian pharmaceutical company focused on APIs, finished dosage formulations, and contract development and manufacturing services.
- Notable point: Laurus Labs is known for antiretroviral medicines and has been expanding into non-ARV APIs, CDMO services, biotechnology, and specialty ingredients.